<![CDATA[Genmab — Juli 2025]]>Doing Great Two Years on My Epcoritamab Trial: Time to Stop? https://cllsociety.org/2025/06/doing-great-two-years-on-my-epcoritamab-trial-time-to-stop/

]]>https://dev.proinvestor.com/forum/topic/399198/genmab-juli-2025RSS for NodeSun, 07 Jun 2026 01:01:14 GMTTue, 01 Jul 2025 05:45:32 GMT60<![CDATA[Reply to Genmab — Juli 2025 on Thu, 31 Jul 2025 18:08:19 GMT]]>Trump sender brev til Novo Nordisk: Kræver prissænkning https://proinvestor.com/boards/127491

]]>https://dev.proinvestor.com/forum/post/7684579https://dev.proinvestor.com/forum/post/7684579Thu, 31 Jul 2025 18:08:19 GMT<![CDATA[Reply to Genmab — Juli 2025 on Thu, 31 Jul 2025 15:14:58 GMT]]>Tak for den

]]>https://dev.proinvestor.com/forum/post/7684577https://dev.proinvestor.com/forum/post/7684577Thu, 31 Jul 2025 15:14:58 GMT<![CDATA[Reply to Genmab — Juli 2025 on Thu, 31 Jul 2025 15:14:18 GMT]]>Fra Abbvie: Global Elahere net revenues were $159 million, an increase of 24.2 percent on a reported basis, or 23.7 percent on an operational basis.

]]>https://dev.proinvestor.com/forum/post/7684578https://dev.proinvestor.com/forum/post/7684578Thu, 31 Jul 2025 15:14:18 GMT<![CDATA[Reply to Genmab — Juli 2025 on Thu, 31 Jul 2025 12:10:54 GMT]]>https://news.abbvie.com/2025-07-31-AbbVie-Reports-Second-Quarter-2025-Financial-Results Epkinly Q2 2025 AbbVie 22 + 48 = 70

]]>https://dev.proinvestor.com/forum/post/7684575https://dev.proinvestor.com/forum/post/7684575Thu, 31 Jul 2025 12:10:54 GMT<![CDATA[Reply to Genmab — Juli 2025 on Thu, 31 Jul 2025 11:57:43 GMT]]>Det undrede godt nok også mig at man tilsyneladende kan nøjes med et meget beskedent bud, og ledelsen anbefaler endda budet?..... Det kunne være rart, hvis vi kunne få nogle kommentarer fra nogle herinde, som har været tæt på nogle M&A indenfor sektoren...

]]>https://dev.proinvestor.com/forum/post/7684574https://dev.proinvestor.com/forum/post/7684574Thu, 31 Jul 2025 11:57:43 GMT<![CDATA[Reply to Genmab — Juli 2025 on Thu, 31 Jul 2025 11:05:57 GMT]]>Gad vide om Genmab er i færd med at lave en BAVA ? At kursen på aktien skal holdes i stram snor - og så kommer der et meget beskeden bud på selskabet. Tanken er ikke så fjern. Gad vide om det der sker om aktiehandel er hel pænt i kanten ?

]]>https://dev.proinvestor.com/forum/post/7684576https://dev.proinvestor.com/forum/post/7684576Thu, 31 Jul 2025 11:05:57 GMT<![CDATA[Reply to Genmab — Juli 2025 on Tue, 29 Jul 2025 06:29:24 GMT]]>Tak lahn - og god formiddag alle.

]]>https://dev.proinvestor.com/forum/post/7684570https://dev.proinvestor.com/forum/post/7684570Tue, 29 Jul 2025 06:29:24 GMT<![CDATA[Reply to Genmab — Juli 2025 on Mon, 28 Jul 2025 05:18:56 GMT]]>Hov det var videon. Her er præsentation. https://ir.genmab.com/static-files/da696dd4-c1be-4903-83b9-99b73bba55c8

]]>https://dev.proinvestor.com/forum/post/7684580https://dev.proinvestor.com/forum/post/7684580Mon, 28 Jul 2025 05:18:56 GMT<![CDATA[Reply to Genmab — Juli 2025 on Mon, 28 Jul 2025 05:17:04 GMT]]>Bikube, det er de samme 2 AE som blev nævnt i post ASCO præsentationen d. 2 juni. Hvor analytikkerne også spurgte ind til det. En pt havde mange comorbidities og døde as septic shock og den andens død blev ikke bedømt at være grundet Rina-S. Se side 12 . https://genmab-2025-post-asco-virtual-rd-update-june25.open-exchange.net/replay

]]>https://dev.proinvestor.com/forum/post/7684568https://dev.proinvestor.com/forum/post/7684568Mon, 28 Jul 2025 05:17:04 GMT<![CDATA[Reply to Genmab — Juli 2025 on Sat, 26 Jul 2025 18:18:47 GMT]]>Rigtig flot transcript. Jeg synes dog, at Tahi kommer lidt let henover "Two fatal AE´s in 120Mg", men det var jo nok en del af grunden til kun at fortsætte med 100 Mg.

]]>https://dev.proinvestor.com/forum/post/7684571https://dev.proinvestor.com/forum/post/7684571Sat, 26 Jul 2025 18:18:47 GMT<![CDATA[Reply to Genmab — Juli 2025 on Sat, 26 Jul 2025 12:35:45 GMT]]>Spændende og bekræftende læsning. Og så skal man skrive sig bag øret, at de 2 mia $ kun er i onkologi. Som de angiver virker det sandsynligt, at Rina-S også virker i andre solide kræftformer. Altså er de 2 mis måske slet ikke i nærheden af et muligt topsalg.

]]>https://dev.proinvestor.com/forum/post/7684569https://dev.proinvestor.com/forum/post/7684569Sat, 26 Jul 2025 12:35:45 GMT<![CDATA[Reply to Genmab — Juli 2025 on Sat, 26 Jul 2025 07:05:56 GMT]]>Ugens danske Vindere & Tabere: Endelig en super-uge for dansk life science https://proinvestor.com/investornyt/1343406/ugens-danske-vindere-amp-tabere-endelig-en-super-uge-for-dansk-life-science

]]>https://dev.proinvestor.com/forum/post/7684581https://dev.proinvestor.com/forum/post/7684581Sat, 26 Jul 2025 07:05:56 GMT<![CDATA[Reply to Genmab — Juli 2025 on Sat, 26 Jul 2025 07:03:22 GMT]]>Teknisk: Genmab bryder op gennem 200 MA, mere i vente mandag https://proinvestor.com/investornyt/1343407/teknisk-genmab-bryder-op-gennem-200-ma-mere-i-vente-mandag

]]>https://dev.proinvestor.com/forum/post/7684573https://dev.proinvestor.com/forum/post/7684573Sat, 26 Jul 2025 07:03:22 GMT<![CDATA[Reply to Genmab — Juli 2025 on Sat, 26 Jul 2025 06:20:38 GMT]]>ESMO 2025 1166P - Tisotumab Vedotin Plus Carboplatin or Pembrolizumab in Recurrent or Metastatic Cervical Cancer: 5-Year Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

]]>https://dev.proinvestor.com/forum/post/7684567https://dev.proinvestor.com/forum/post/7684567Sat, 26 Jul 2025 06:20:38 GMT<![CDATA[Reply to Genmab — Juli 2025 on Sat, 26 Jul 2025 06:19:22 GMT]]>ESMO 2025 1121P - Rinatabart sesutecan (Rina-S®) for patients with advanced or recurrent endometrial cancer (a/r EC): Update from dose expansion cohort B2 of RAINFOL™-01

]]>https://dev.proinvestor.com/forum/post/7684566https://dev.proinvestor.com/forum/post/7684566Sat, 26 Jul 2025 06:19:22 GMT<![CDATA[Reply to Genmab — Juli 2025 on Sat, 26 Jul 2025 06:12:57 GMT]]>ESMO 2025 Industry Satellite Symposium

Genmab - Advancing Antibody-Drug Conjugates Into the Future of Gynecologic Malignancies https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal/session/calendar?q=genmab

]]>https://dev.proinvestor.com/forum/post/7684563https://dev.proinvestor.com/forum/post/7684563Sat, 26 Jul 2025 06:12:57 GMT<![CDATA[Reply to Genmab — Juli 2025 on Sat, 26 Jul 2025 05:27:29 GMT]]>Tak til ØU for fremskaffelse og udarbejdelse af fortrinligt materiale.

]]>https://dev.proinvestor.com/forum/post/7684564https://dev.proinvestor.com/forum/post/7684564Sat, 26 Jul 2025 05:27:29 GMT<![CDATA[Reply to Genmab — Juli 2025 on Sat, 26 Jul 2025 04:36:13 GMT]]>Genmab Transcript Special Call: Ser Rina-S i markedet i 2027 med peak-salg på 2 mia. USD https://proinvestor.com/investornyt/1343403/genmab-transcript-special-call-ser-rina-s-i-markedet-i-2027-med-peak-salg-pa-2-mia-usd

]]>https://dev.proinvestor.com/forum/post/7684565https://dev.proinvestor.com/forum/post/7684565Sat, 26 Jul 2025 04:36:13 GMT<![CDATA[Reply to Genmab — Juli 2025 on Sat, 26 Jul 2025 03:46:39 GMT]]>God morgen 🙂

]]>https://dev.proinvestor.com/forum/post/7684572https://dev.proinvestor.com/forum/post/7684572Sat, 26 Jul 2025 03:46:39 GMT<![CDATA[Reply to Genmab — Juli 2025 on Sat, 26 Jul 2025 03:12:51 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/7684559https://dev.proinvestor.com/forum/post/7684559Sat, 26 Jul 2025 03:12:51 GMT<![CDATA[Reply to Genmab — Juli 2025 on Fri, 25 Jul 2025 08:23:27 GMT]]>Thanks a lot for the extra info.

]]>https://dev.proinvestor.com/forum/post/7684560https://dev.proinvestor.com/forum/post/7684560Fri, 25 Jul 2025 08:23:27 GMT<![CDATA[Reply to Genmab — Juli 2025 on Fri, 25 Jul 2025 08:21:46 GMT]]>But both Özlem Türeci & Uğur Şahin from biontech co-authored it, so they must have deemed it of interest

]]>https://dev.proinvestor.com/forum/post/7684558https://dev.proinvestor.com/forum/post/7684558Fri, 25 Jul 2025 08:21:46 GMT<![CDATA[Reply to Genmab — Juli 2025 on Fri, 25 Jul 2025 08:20:39 GMT]]>whether those preclinical activities aim to return with something on Hexabody-CD27 I don't know (but i doubt it). Maybe it is to get more info on the Hexabody technology

]]>https://dev.proinvestor.com/forum/post/7684555https://dev.proinvestor.com/forum/post/7684555Fri, 25 Jul 2025 08:20:39 GMT<![CDATA[Reply to Genmab — Juli 2025 on Fri, 25 Jul 2025 08:18:50 GMT]]>this is what it said last august24: Following a strategic evaluation of GEN1053 within the context of
Genmab’s and BioNTech’s portfolios, a decision was made to discontinue the Phase 1/2 clinical trial
(NCT05435339) of GEN1053 in solid tumors. Preclinical activities remain ongoing.

]]>https://dev.proinvestor.com/forum/post/7684561https://dev.proinvestor.com/forum/post/7684561Fri, 25 Jul 2025 08:18:50 GMT